niacinamide has been researched along with Cancer of Larynx in 13 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Samples were available from 157 T2-T4 laryngeal cancer and 185 T1-T4a bladder cancer patients enrolled on the accelerated radiotherapy with carbogen and nicotinamide (ARCON) and bladder carbogen nicotinamide (BCON) phase III randomized trials of radiotherapy alone or with carbogen and nicotinamide (CON) respectively." | 5.17 | A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer. ( Betts, GN; Buffa, FM; Denley, H; Eustace, A; Harris, AL; Homer, JJ; Hoskin, PJ; Irlam, JJ; Kaanders, JH; Mani, N; Miller, CJ; Rojas, AM; Span, PN; Taylor, J; West, CM, 2013) |
| "In both laryngeal squamous cell carcinoma xenograft tumour lines carbogen was very effective in reducing diffusion limited hypoxia." | 3.70 | Vascular architecture and microenvironmental parameters in human squamous cell carcinoma xenografts: effects of carbogen and nicotinamide. ( Bussink, J; Hodgkiss, RJ; Kaanders, JH; Marres, HA; Peters, JP; Rijken, PF; van der Kogel, AJ, 1999) |
| "Of 345 patients with cT2-4 laryngeal cancer, 174 were randomly assigned to accelerated radiotherapy and 171 to ARCON." | 2.79 | Improved recurrence-free survival with ARCON for anemic patients with laryngeal cancer. ( Bijl, HP; Bussink, J; Chin, A; de Bree, R; Doornaert, PA; Hoogsteen, IJ; Janssens, GO; Kaanders, JH; Rademakers, SE; Span, PN; Takes, RP; Terhaard, CH; van den Ende, P, 2014) |
| "Patients with cT2-4 squamous cell laryngeal cancer were randomly assigned to AR (68 Gy within 36 to 38 days) or ARCON." | 2.77 | Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. ( Bijl, HP; Bussink, J; Chin, A; de Bree, R; Doornaert, PA; Hoogsteen, IJ; Janssens, GO; Kaanders, JH; Marres, HA; Rademakers, SE; Span, PN; Terhaard, CH; van den Ende, P; van der Kogel, AJ, 2012) |
| "Of 345 patients with cT2-4 laryngeal cancer, pre-treatment computed tomography (CT) scans of 270 patients were available for tumour volume calculation." | 1.40 | Computed tomography-based tumour volume as a predictor of outcome in laryngeal cancer: results of the phase 3 ARCON trial. ( Bijl, HP; de Jong, MA; Doornaert, PA; Janssens, GO; Kaanders, JH; Span, PN; Terhaard, CH; van Bockel, LW; van den Broek, GB; van den Ende, P; Verbist, BM, 2014) |
| " It is our conclusion that radiotherapy combined with carbogen and nicotinamide is a safe treatment with manageable side effects." | 1.29 | Radiotherapy with carbogen breathing and nicotinamide in head and neck cancer: feasibility and toxicity. ( Kaanders, JH; Marres, HA; Pop, LA; van Daal, WA; van der Kogel, AJ; van der Maazen, RW, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rademakers, SE | 4 |
| Hoogsteen, IJ | 4 |
| Rijken, PF | 3 |
| Oosterwijk, E | 1 |
| Terhaard, CH | 7 |
| Doornaert, PA | 7 |
| Langendijk, JA | 3 |
| van den Ende, P | 7 |
| Takes, R | 1 |
| De Bree, R | 3 |
| van der Kogel, AJ | 6 |
| Bussink, J | 5 |
| Kaanders, JH | 11 |
| Eustace, A | 1 |
| Mani, N | 1 |
| Span, PN | 5 |
| Irlam, JJ | 1 |
| Taylor, J | 1 |
| Betts, GN | 1 |
| Denley, H | 1 |
| Miller, CJ | 1 |
| Homer, JJ | 1 |
| Rojas, AM | 1 |
| Hoskin, PJ | 1 |
| Buffa, FM | 1 |
| Harris, AL | 1 |
| West, CM | 1 |
| Janssens, GO | 5 |
| van Bockel, LW | 1 |
| Bijl, HP | 4 |
| de Jong, MA | 2 |
| van den Broek, GB | 1 |
| Verbist, BM | 1 |
| Chin, A | 3 |
| Takes, RP | 2 |
| Pop, LA | 3 |
| Hinojar-Gutiérrez, A | 1 |
| Nieto-Llanos, S | 1 |
| Mera-Menéndez, F | 1 |
| Fernández-Contreras, ME | 1 |
| Mendoza, J | 1 |
| Moreno, R | 1 |
| Peters, L | 1 |
| Rischin, D | 1 |
| Marres, HA | 4 |
| van der Maazen, RW | 1 |
| van Daal, WA | 2 |
| Liefers, J | 1 |
| van den Hoogen, FJ | 1 |
| Peters, JP | 1 |
| Hodgkiss, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicentre, Randomised, Phase III Clinical Trial Comparing Accelerated Radiotherapy With Accelerated Radiotherapy Plus Carbogen and Nicotinamide (ARCON) in Clinical Stage T2-4 Laryngeal Carcinoma.[NCT00147732] | Phase 3 | 345 participants (Actual) | Interventional | 2001-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 trials available for niacinamide and Cancer of Larynx
| Article | Year |
|---|---|
Pattern of CAIX expression is prognostic for outcome and predicts response to ARCON in patients with laryngeal cancer treated in a phase III randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Carbon Dioxide; Carbonic Anhydrase IX; Carbonic | 2013 |
A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer.
Topics: Carbon Dioxide; Cell Hypoxia; Female; Gene Expression Regulation, Neoplastic; Humans; Laryngeal Neop | 2013 |
Prognostic value of the proliferation marker Ki-67 in laryngeal carcinoma: results of the accelerated radiotherapy with carbogen breathing and nicotinamide phase III randomized trial.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Carbon Dioxide; Carb | 2015 |
Improved recurrence-free survival with ARCON for anemic patients with laryngeal cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Biomarkers; Carbon Dioxide; Female; Hemoglobins; Humans; Hyp | 2014 |
Quality-of-life after radiotherapy for advanced laryngeal cancer: Results of a phase III trial of the Dutch Head and Neck Society.
Topics: Adult; Aged; Aged, 80 and over; Carbon Dioxide; Female; Follow-Up Studies; Head and Neck Neoplasms; | 2016 |
Acute toxicity profile and compliance to accelerated radiotherapy plus carbogen and nicotinamide for clinical stage T2-4 laryngeal cancer: results of a phase III randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Carbon Dioxide; Carcinoma, Squamous Cell; Deglut | 2012 |
Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial.
Topics: Administration, Inhalation; Administration, Oral; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; | 2012 |
6 other studies available for niacinamide and Cancer of Larynx
| Article | Year |
|---|---|
Computed tomography-based tumour volume as a predictor of outcome in laryngeal cancer: results of the phase 3 ARCON trial.
Topics: Carbon Dioxide; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Disease-Free Surviva | 2014 |
Laryngeal metastasis as first presentation of hepatocellular carcinoma.
Topics: Adenoma, Oxyphilic; Antineoplastic Agents; Biopsy, Fine-Needle; Carcinoma, Hepatocellular; Combined | 2011 |
Elusive goal of targeting tumor hypoxia for therapeutic gain.
Topics: Carbon Dioxide; Carcinoma, Squamous Cell; Female; Humans; Laryngeal Neoplasms; Male; Niacinamide; Ox | 2012 |
Radiotherapy with carbogen breathing and nicotinamide in head and neck cancer: feasibility and toxicity.
Topics: Administration, Inhalation; Administration, Oral; Adult; Aged; Aged, 80 and over; Carbon Dioxide; Ca | 1995 |
Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer.
Topics: Actuarial Analysis; Administration, Inhalation; Administration, Oral; Adult; Aged; Aged, 80 and over | 1998 |
Vascular architecture and microenvironmental parameters in human squamous cell carcinoma xenografts: effects of carbogen and nicotinamide.
Topics: Animals; Benzimidazoles; Blood Vessels; Carbon Dioxide; Carcinoma, Squamous Cell; Cell Division; End | 1999 |